386 related articles for article (PubMed ID: 15161435)
61. [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
Shukuya T; Takahashi T; Nakamura Y; Yamamoto N
Gan To Kagaku Ryoho; 2010 Mar; 37(3):487-90. PubMed ID: 20332689
[TBL] [Abstract][Full Text] [Related]
62. Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
Suwanrusme H; Meyer ML; Green MR
Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S56-60. PubMed ID: 15117426
[TBL] [Abstract][Full Text] [Related]
63. Malignant pleural mesothelioma: current concepts in treatment.
Tsiouris A; Walesby RK
Nat Clin Pract Oncol; 2007 Jun; 4(6):344-52. PubMed ID: 17534390
[TBL] [Abstract][Full Text] [Related]
64. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
Solomon B; Bunn PA
Future Oncol; 2005 Dec; 1(6):733-46. PubMed ID: 16556051
[TBL] [Abstract][Full Text] [Related]
65. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice.
Cordony A; Le Reun C; Smala A; Symanowski JT; Watkins J
Value Health; 2008; 11(1):4-12. PubMed ID: 18237355
[TBL] [Abstract][Full Text] [Related]
66. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; CollovĂ E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
67. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Cancer; 2004 Aug; 101(3):587-95. PubMed ID: 15274072
[TBL] [Abstract][Full Text] [Related]
68. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature.
Brandes JC; Grossman SA; Ahmad H
Cancer Invest; 2006; 24(3):283-7. PubMed ID: 16809156
[TBL] [Abstract][Full Text] [Related]
69. Pemetrexed-associated urticarial vasculitis.
Lopes G; Vincek V; Raez LE
Lung Cancer; 2006 Feb; 51(2):247-9. PubMed ID: 16360237
[TBL] [Abstract][Full Text] [Related]
70. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
Kuribayashi K; Voss S; Nishiuma S; Arakawa K; Nogi Y; Mikami K; Kudoh S
Lung Cancer; 2012 Mar; 75(3):353-9. PubMed ID: 21890228
[TBL] [Abstract][Full Text] [Related]
71. Standard therapy for the treatment of malignant pleural mesothelioma.
Vogelzang NJ
Lung Cancer; 2005 Oct; 50 Suppl 1():S23-4. PubMed ID: 16291429
[TBL] [Abstract][Full Text] [Related]
72. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
73. The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
Fizazi K; John WJ; Vogelzang NJ
Semin Oncol; 2002 Feb; 29(1):77-81. PubMed ID: 11836672
[TBL] [Abstract][Full Text] [Related]
74. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; De Vincenzo F; Gianoncelli L; Simonelli M; Lorenzi E; Ripa C; Giordano L; Santoro A
Lung Cancer; 2011 Apr; 72(1):73-7. PubMed ID: 21216487
[TBL] [Abstract][Full Text] [Related]
75. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
Rusch VW
J Clin Oncol; 2003 Jul; 21(14):2629-30. PubMed ID: 12860935
[No Abstract] [Full Text] [Related]
76. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Scagliotti GV; Selvaggi G
Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
[TBL] [Abstract][Full Text] [Related]
77. Current concepts in chemotherapy for malignant pleural mesothelioma.
Sørensen JB
Clin Respir J; 2008 Apr; 2(2):74-9. PubMed ID: 20298310
[TBL] [Abstract][Full Text] [Related]
78. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
79. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
[TBL] [Abstract][Full Text] [Related]
80. Raltitrexed in mesothelioma.
Surmont VF; van Meerbeeck JP
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1481-90. PubMed ID: 21999120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]